Compensatory induction of MYC expression by sustained CDK9 inhibition via a BRD4-dependent mechanism

eLife

Volumn 4, Issue JUNE2015, 2015, Pages

  Lu, Huasong ^a,b   Xue, Yuahua ^b   Yu, Guoying K ^c   Arias, Carolina ^c   Lin, Julie ^c   Fong, Susan ^c   Faure, Michel ^c   Weisburd, Ben ^c   Ji, Xiaodan ^a   Mercier, Alexandre ^c   Sutton, James ^c   Luo, Kunxin ^a   Gao, Zhenhai ^c   Zhou, Qiang ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b XIAMEN UNIVERSITY   (China)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO [3,2 F] [1,2,4] TRIAZOLO [4,3 A] [1,4] DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; CYCLIN DEPENDENT KINASE 3; CYCLIN DEPENDENT KINASE 5; CYCLIN DEPENDENT KINASE 7; CYCLIN DEPENDENT KINASE 9; CYCLIN DEPENDENT KINASE 9 INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR; DIMETHYL SULFOXIDE; FLAVOPIRIDOL; MESSENGER RNA; MYC PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; POLYCLONAL ANTIBODY; POSITIVE TRANSCRIPTION ELONGATION FACTOR B; PROTEIN; PROTEIN BRD4; PROTEIN MCL 1; RNA POLYMERASE II; SMALL NUCLEAR RIBONUCLEOPROTEIN; TRANSCRIPTION ELONGATION FACTOR; UNCLASSIFIED DRUG; BRD4 PROTEIN, HUMAN; CDK9 PROTEIN, HUMAN; MYC PROTEIN, HUMAN; NUCLEAR PROTEIN; TRANSCRIPTION FACTOR;

APOPTOSIS; ARTICLE; CANCER CELL LINE; CELL GROWTH; CHROMATIN IMMUNOPRECIPITATION; COMPETITIVE BINDING ASSAY; CONTROLLED STUDY; DNA MICROARRAY; ENZYME INHIBITION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC50; INTRACELLULAR SIGNALING; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN FOLDING; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; RNA PROCESSING; SEQUENCE ANALYSIS; TRANSCRIPTION ELONGATION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; METABOLISM;

CYCLIN-DEPENDENT KINASE 9; GENE EXPRESSION REGULATION; HUMANS; NUCLEAR PROTEINS; POSITIVE TRANSCRIPTIONAL ELONGATION FACTOR B; PROTO-ONCOGENE PROTEINS C-MYC; TRANSCRIPTION FACTORS;

EID: 84937053463     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.06535     Document Type: Article

References (70)

1. Amati B, Brooks MW, Levy N, Littlewood TD, Evan GI, Land H. 1993. Oncogenic activity of the c-Myc protein requires dimerization with Max. Cell 72:233-245. doi:10.1016/0092-8674(93)90663-B.
2. Barboric M, Yik JH, Czudnochowski N, Yang Z, Chen R, Contreras X, Geyer M, Matija Peterlin B, Zhou Q. 2007. Tat competes with HEXIM1 to increase the active pool of P-TEFb for HIV-1 transcription. Nucleic Acids Research 35: 2003-2012. doi:10.1093/nar/gkm063.
3. Bartholomeeusen K, Xiang Y, Fujinaga K, Peterlin BM. 2012. Bromodomain and extra-terminal (BET) bromodomain inhibition activate transcription via transient release of positive transcription elongation factor b (P-TEFb) from 7SK small nuclear ribonucleoprotein. The Journal of Biological Chemistry 287:36609-36616. doi:10.1074/jbc.M112.410746.
4. Bartkowiak B, Liu P, Phatnani HP, Fuda NJ, Cooper JJ, Price DH, Adelman K, Lis JT, Greenleaf AL. 2010.CDK12 is a transcription elongation-associated CTD kinase, the metazoan ortholog of yeast Ctk1. Genes & Development 24:2303-2316. doi:10.1101/gad.1968210.
5. Bentley DL, Groudine M. 1986. A block to elongation is largely responsible for decreased transcription of c-myc in differentiated HL60 cells. Nature 321:702-706. doi:10.1038/321702a0.
6. Bible KC, Bible RH Jr, Kottke TJ, Svingen PA, Xu K, Pang YP, Hajdu E, Kaufmann SH. 2000. Flavopiridol binds to duplex DNA. Cancer Research 60:2419-2428.
7. Bisgrove DA, Mahmoudi T, Henklein P, Verdin E. 2007. Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription. Proceedings of the National Academy of Sciences of the United States of America 104: 13690-13695. doi:10.1073/pnas.0705053104.
8. Blagosklonny MV. 2004. Flavopiridol, an inhibitor of transcription: implications, problems and solutions. Cell Cycle 3:1537-1542. doi:10.4161/cc.3.12.1278.
9. Bosken CA, Farnung L, Hintermair C, Merzel Schachter M, Vogel-Bachmayr K, Blazek D, Anand K, Fisher RP, Eick D, Geyer M. 2014. The structure and substrate specificity of human Cdk12/Cyclin K. Nature Communications 5: 3505. doi:10.1038/ncomms4505.
10. Chao SH, Fujinaga K, Marion JE, Taube R, Sausville EA, Senderowicz AM, Peterlin BM, Price DH. 2000. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. The Journal of Biological Chemistry 275:28345-28348. doi:10.1074/jbc.C000446200.
11. Chao SH, Price DH. 2001. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. The Journal of Biological Chemistry 276:31793-31799. doi:10.1074/jbc.M102306200.
12. Chen R, Wierda WG, Chubb S, Hawtin RE, Fox JA, Keating MJ, Gandhi V, Plunkett W. 2009. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood 113:4637-4645. doi:10.1182/blood-2008-12-190256.
13. Dai M, Wang P, Boyd AD, Kostov G, Athey B, Jones EG, Bunney WE, Myers RM, Speed TP, Akil H, Watson SJ, Meng F. 2005. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Research 33:e175. doi:10.1093/nar/gni179.
14. Dang CV. 2012. MYC on the path to cancer. Cell 149:22-35. doi:10.1016/j.cell.2012.03.003.
15. Devaiah BN, Lewis BA, Cherman N, Hewitt MC, Albrecht BK, Robey PG, Ozato K, Sims RJ III, Singer DS. 2012. BRD4 is an atypical kinase that phosphorylates serine2 of the RNA polymerase II carboxy-terminal domain. Proceedings of the National Academy of Sciences of USA 109:6927-6932. doi:10.1073/pnas.1120422109.
16. Di Vona C, Bezdan D, Islam AB, Salichs E, Lopez-Bigas N, Ossowski S, de la Luna S. 2015. Chromatin-wide profiling of DYRK1A reveals a role as a gene-specific RNA polymerase II CTD kinase. Molecular Cell 57:506-520. doi:10.1016/j.molcel.2014.12.026.
17. Fabian MA, Biggs WH III, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG, Carter TA, Ciceri P, Edeen PT, Floyd M, Galvin M, Gerlach JL, Grotzfeld RM, Herrgard S, Insko DE, Insko MA, Lai AG, Lélias JM, Mehta SA, Milanov ZV, Velasco AM, Wodicka LM, Patel HK, Zarrinkar PP, Lockhart DJ. 2005. A small molecule-kinase interaction map for clinical kinase inhibitors. Nature Biotechnology 23:329-336. doi:10.1038/nbt1068.
18. Filippakopoulos P, Knapp S. 2014. Targeting bromodomains: epigenetic readers of lysine acetylation. Nature Reviews. Drug Discovery 13:337-356. doi:10.1038/nrd4286.
19. Fisher RP. 2010.Coming full circle: cyclin-dependent kinases as anti-cancer drug targets. Sub-Cellular Biochemistry 50:1-15. doi:10.1007/978-90-481-3471-7_1.
20. Fowler T, Sen R, Roy AL. 2011. Regulation of primary response genes. Molecular Cell 44:348-360. doi:10.1016/j.molcel.2011.09.014.
21. Garber ME, Mayall TP, Suess EM, Meisenhelder J, Thompson NE, Jones KA. 2000. CDK9 autophosphorylation regulates high-affinity binding of the human immunodeficiency virus type 1 tat-P-TEFb complex to TAR RNA. Molecular and Cellular Biology 20:6958-6969. doi:10.1128/MCB.20.18.6958-6969.2000.
22. Guenther MG, Levine SS, Boyer LA, Jaenisch R, Young RA. 2007. A chromatin landmark and transcription initiation at most promoters in human cells. Cell 130:77-88. doi:10.1016/j.cell.2007.05.042.
23. Hargreaves DC, Horng T, Medzhitov R. 2009. Control of inducible gene expression by signal-dependent transcriptional elongation. Cell 138:129-145. doi:10.1016/j.cell.2009.05.047.
24. He N, Liu M, Hsu J, Xue Y, Chou S, Burlingame A, Krogan NJ, Alber T, Zhou Q. 2010.HIV-1 Tat and host AFF4 recruit two transcription elongation factors into a bifunctional complex for coordinated activation of HIV-1 transcription. Molecular Cell 38:428-438. doi:10.1016/j.molcel.2010.04.013.
25. He N, Pezda AC, Zhou Q. 2006. Modulation of a P-TEFb functional equilibrium for the global control of cell growth and differentiation. Molecular and Cellular Biology 26:7068-7076. doi:10.1128/MCB.00778-06.
26. Huang CH, Lujambio A, Zuber J, Tschaharganeh DF, Doran MG, Evans MJ, Kitzing T, Zhu N, de Stanchina E, Sawyers CL, Armstrong SA, Lewis JS, Sherr CJ, Lowe SW. 2014. CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. Genes & Development 28:1800-1814. doi:10.1101/gad.244368.114.
27. Huang da W, Sherman BT, Lempicki RA. 2009. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature Protocols 4:44-57. doi:10.1038/nprot.2008.211.
28. Itzen F, Greifenberg AK, Bosken CA, Geyer M. 2014. Brd4 activates P-TEFb for RNA polymerase II CTD phosphorylation. Nucleic Acids Research 42:7577-7590. doi:10.1093/nar/gku449.
29. Jang MK, Mochizuki K, Zhou M, Jeong HS, Brady JN, Ozato K. 2005. The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Molecular Cell 19: 523-534. doi:10.1016/j.molcel.2005.06.027.
30. Kanazawa S, Soucek L, Evan G, Okamoto T, Peterlin BM. 2003. c-Myc recruits P-TEFb for transcription, cellular proliferation and apoptosis. Oncogene 22:5707-5711. doi:10.1038/sj.onc.1206800.
31. Keskin H, Garriga J, Georlette D, Grana X. 2012. Complex effects of flavopiridol on the expression of primary response genes. Cell Division 7:11. doi:10.1186/1747-1028-7-11.
32. Knockaert M, Greengard P, Meijer L. 2002. Pharmacological inhibitors of cyclin-dependent kinases. Trends in Pharmacological Sciences 23:417-425. doi:10.1016/S0165-6147(02)02071-0.
33. Kuras L, Struhl K. 1999. Binding of TBP to promoters in vivo is stimulated by activators and requires Pol II holoenzyme. Nature 399:609-613. doi:10.1038/21239.
34. Langmead B, Salzberg SL. 2012. Fast gapped-read alignment with Bowtie 2. Nature Methods 9:357-359. doi:10.1038/nmeth.1923.
35. Levens D. 2013. Cellular MYCro economics: Balancing MYC function with MYC expression. Cold Spring Harbor Perspectives in Medicine 3:a014233. doi:10.1101/cshperspect.a014233.
36. Levine M. 2011. Paused RNA polymerase II as a developmental checkpoint. Cell 145:502-511. doi:10.1016/j.cell.2011.04.021.
37. Li Z, Guo J, Wu Y, Zhou Q. 2013. The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation. Nucleic Acids Research 41:277-287. doi:10.1093/nar/gks976.
38. Lin C, Smith ER, Takahashi H, Lai KC, Martin-Brown S, Florens L, Washburn MP, Conaway JW, Conaway RC, Shilatifard A. 2010.AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. Molecular Cell 37:429-437. doi:10.1016/j.molcel.2010.01.026.
39. Liu W, Ma Q, Wong K, Li W, Ohgi K, Zhang J, Aggarwal AK, Rosenfeld MG. 2013. Brd4 and JMJD6-associated antipause enhancers in regulation of transcriptional pause release. Cell 155:1581-1595. doi:10.1016/j.cell.2013.10.056.
40. Lu H, Li Z, Xue Y, Schulze-Gahmen U, Johnson JR, Krogan NJ, Alber T, Zhou Q. 2014. AFF1 is a ubiquitous P-TEFb partner to enable Tat extraction of P-TEFb from 7SK snRNP and formation of SECs for HIV transactivation. Proceedings of the National Academy of Sciences of USA 111:E15-E24. doi:10.1073/pnas.1318503111.
41. Lu H, Li Z, Xue Y, Zhou Q. 2013. Viral-host interactions that control HIV-1 transcriptional elongation. Chemical Reviews 113:8567-8582. doi:10.1021/cr400120z.
42. Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, Mele DA, Bergeron L, Sims RJ III. 2011. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proceedings of the National Academy of Sciences of USA 108:16669-16674. doi:10.1073/pnas.1108190108.
43. Meyer N, Penn LZ. 2008. Reflecting on 25 years with MYC. Nature Reviews. Cancer 8:976-990. doi:10.1038/nrc2231.
44. Mueller D, Garcia-Cuellar MP, Bach C, Buhl S, Maethner E, Slany RK. 2009. Misguided transcriptional elongation causes mixed lineage leukemia. PLOS Biology 7:e1000249. doi:10.1371/journal.pbio.1000249.
45. Muse GW, Gilchrist DA, Nechaev S, Shah R, Parker JS, Grissom SF, Zeitlinger J, Adelman K. 2007. RNA polymerase is poised for activation across the genome. Nature Genetics 39:1507-1511. doi:10.1038/ng.2007.21.
46. Nguyen VT, Kiss T, Michels AA, Bensaude O. 2001. 7SK small nuclear RNA binds to and inhibits the activity of CDK9/cyclin T complexes. Nature 414:322-325. doi:10.1038/35104581.
47. Nie Z, Hu G, Wei G, Cui K, Yamane A, Resch W, Wang R, Green DR, Tessarollo L, Casellas R, Zhao K, Levens D. 2012. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell 151:68-79. doi:10.1016/j.cell.2012.08.033.
48. Ptashne M. 2005. Regulation of transcription: from lambda to eukaryotes. Trends in Biochemical Sciences 30: 275-279. doi:10.1016/j.tibs.2005.04.003.
49. Pufall MA, Kaplan CD. 2013. Mechanisms of eukaryotic transcription. Genome Biology 14:311. doi:10.1186/gb4132.
50. Rahl PB, Lin CY, Seila AC, Flynn RA, McCuine S, Burge CB, Sharp PA, Young RA. 2010.c-Myc regulates transcriptional pause release. Cell 141:432-445. doi:10.1016/j.cell.2010.03.030.
51. Schulze-Gahmen U, Lu H, Zhou Q, Alber T. 2014. AFF4 binding to Tat-P-TEFb indirectly stimulates TAR recognition of super elongation complexes at the HIV promoter. eLife 3:e02375. doi:10.7554/eLife.02375.
52. Sedore SC, Byers SA, Biglione S, Price JP, Maury WJ, Price DH. 2007. Manipulation of P-TEFb control machinery by HIV: recruitment of P-TEFb from the large form by Tat and binding of HEXIM1 to TAR. Nucleic Acids Research 35: 4347-4358. doi:10.1093/nar/gkm443.
53. Senderowicz AM, Sausville EA. 2000. Preclinical and clinical development of cyclin-dependent kinase modulators. Journal of the National Cancer Institute 92:376-387. doi:10.1093/jnci/92.5.376.
54. Shi J, Vakoc CR. 2014. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Molecular Cell 54:728-736. doi:10.1016/j.molcel.2014.05.016.
55. Shim EY, Walker AK, Shi Y, Blackwell TK. 2002. CDK-9/cyclin T (P-TEFb) is required in two postinitiation pathways for transcription in the C. elegans embryo. Genes & Development 16:2135-2146. doi:10.1101/gad.999002.
56. Sobhian B, Laguette N, Yatim A, Nakamura M, Levy Y, Kiernan R, Benkirane M. 2010.HIV-1 Tat assembles a multifunctional transcription elongation complex and stably associates with the 7SK snRNP. Molecular Cell 38: 439-451. doi:10.1016/j.molcel.2010.04.012.
57. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. 2005. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences of USA 102:15545-15550. doi:10.1073/pnas.0506580102.
58. Tallarida RJ. 2001. Drug synergism: its detection and applications. The Journal of Pharmacology and Experimental Therapeutics 298:865-872.
59. Tallarida RJ. 2006. An overview of drug combination analysis with isobolograms. The Journal of Pharmacology and Experimental Therapeutics 319:1-7. doi:10.1124/jpet.106.104117.
60. Tse AN, Rendahl KG, Sheikh T, Cheema H, Aardalen K, Embry M, Ma S, Moler EJ, Ni ZJ, Lopes de Menezes DE, Hibner B, Gesner TG, Schwartz GK. 2007. CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo. Clinical Cancer Research 13:591-602. doi:10.1158/1078-0432.CCR-06-1424.
61. Yang Z, He N, Zhou Q. 2008. Brd4 recruits P-TEFb to chromosomes at late mitosis to promote G1 gene expression and cell cycle progression. Molecular and Cellular Biology 28:967-976. doi:10.1128/MCB.01020-07.
62. Yang Z, Yik JH, Chen R, He N, Jang MK, Ozato K, Zhou Q. 2005. Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Molecular Cell 19:535-545. doi:10.1016/j.molcel.2005.06.029.
63. Yang Z, Zhu Q, Luo K, Zhou Q. 2001. The 7SK small nuclear RNA inhibits the CDK9/cyclin T1 kinase to control transcription. Nature 414:317-322. doi:10.1038/35104575.
64. Yik JH, Chen R, Nishimura R, Jennings JL, Link AJ, Zhou Q. 2003. Inhibition of P-TEFb (CDK9/Cyclin T) kinase and RNA polymerase II transcription by the coordinated actions of HEXIM1 and 7SK snRNA. Molecular Cell 12: 971-982. doi:10.1016/S1097-2765(03)00388-5.
65. Yokoyama A, Lin M, Naresh A, Kitabayashi I, Cleary ML. 2010.A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription. Cancer Cell 17: 198-212. doi:10.1016/j.ccr.2009.12.040.
66. Zeitlinger J, Stark A, Kellis M, Hong JW, Nechaev S, Adelman K, Levine M, Young RA. 2007. RNA polymerase stalling at developmental control genes in the Drosophila melanogaster embryo. Nature Genetics 39:1512-1516. doi:10.1038/ng.2007.26.
67. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, Nusbaum C, Myers RM, Brown M, Li W. 2008. Model-based analysis of ChIP-Seq (MACS). Genome Biology 9:R137. doi:10.1186/gb-2008-9-9-r137.
68. Zhou Q, Li T, Price DH. 2012. RNA polymerase II elongation control. Annual Review of Biochemistry 81:119-143. doi:10.1146/annurev-biochem-052610-095910.
69. Zhou Q, Yik JH. 2006. The Yin and Yang of P-TEFb regulation: implications for human immunodeficiency virus gene expression and global control of cell growth and differentiation. Microbiology and Molecular Biology Reviews 70: 646-659. doi:10.1128/MMBR.00011-06.
70. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, Magoon D, Qi J, Blatt K, Wunderlich M, Taylor MJ, Johns C, Chicas A, Mulloy JC, Kogan SC, Brown P, Valent P, Bradner JE, Lowe SW, Vakoc CR. 2011. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478:524-528. doi:10.1038/nature10334.